Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial - Concepedia

Concepedia

Publication | Closed Access

Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial

221

Citations

20

References

2021

Year

Marcia S. Brose, Bruce Robinson, Steven I. Sherman, Jolanta Krajewska, Chia‐Chi Lin, Fernanda Vaisman, Ana O. Hoff, Erika Hitre, Daniel W. Bowles, Jorge Hernando,

The Lancet Oncology

Nuclear MedicineMedicineRadionuclide TherapyThyroid DiseasePharmacologyRadiopharmaceutical TherapyPharmacotherapyCancer TreatmentThyroid HormoneOncologyRadiation OncologyThyroid CancerCancer ResearchRadiologyHealth Sciences

References

	Year	Citations

Page 1

Page 1